Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Becton Dickinson and Company (BDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,135,948
  • Shares Outstanding, K 227,570
  • Annual Sales, $ 12,093 M
  • Annual Income, $ 1,100 M
  • 36-Month Beta 1.04
  • Price/Sales 4.17
  • Price/Cash Flow 15.81
  • Price/Book 4.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
202.73 +8.67%
on 10/18/17
225.23 -2.18%
on 11/06/17
+17.24 (+8.49%)
since 10/17/17
3-Month
191.53 +15.03%
on 09/21/17
225.23 -2.18%
on 11/06/17
+21.00 (+10.54%)
since 08/17/17
52-Week
161.29 +36.59%
on 12/07/16
225.23 -2.18%
on 11/06/17
+46.89 (+27.04%)
since 11/17/16

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and Dickinson

The Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and Dickinson

BSX : 28.26 (-0.07%)
BDX : 220.31 (-0.55%)
BAX : 63.88 (-1.71%)
ISRG : 392.48 (-0.34%)
Trump Focuses on APAC: 4 MedTech Stocks to Watch

Considering Trump's growing focus on APAC, the region seems to be poised to yield accretive returns over the long term. Favorable MedTech trends in APAC hold promise.

BSX : 28.26 (-0.07%)
BDX : 220.31 (-0.55%)
BAX : 63.88 (-1.71%)
ISRG : 392.48 (-0.34%)
BD to Introduce Integrated Medication Management Platform Designed to Address Hospitals' Greatest Challenges at #ASHP17

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will launch its latest advancement in comprehensive medication management, BD HealthSight(TM) platform for enterprise...

BDX : 220.31 (-0.55%)
BD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's announcement by Merit Medical Systems, Inc. that it has signed...

BCR : 333.56 (-0.21%)
BDX : 220.31 (-0.55%)
MDSY : 0.73 (+4.29%)
Pacific Biosciences (PACB) Q3 Loss Narrower Than Estimated

Pacific Biosciences (PACB) witnesses solid contribution from the Instrument and Consumable revenue platforms. Consumable revenue growth was driven by higher installed base of instruments.

PETS : 38.67 (-1.98%)
PACB : 2.98 (-0.67%)
BDX : 220.31 (-0.55%)
ISRG : 392.48 (-0.34%)
Becton Dickinson (BDX) in Focus: Stock Moves 7.7% Higher

Becton Dickinson (BDX) saw its shares rise nearly 8% on the day after the company posted better-than-expected third-quarter results.

BDX : 220.31 (-0.55%)
ALGN : 253.89 (-0.40%)
Becton, Dickinson (BDX) Beats on Q4 Earnings, Guidance Solid

Becton, Dickinson's (BDX) guidance for fiscal 2018 buoys optimism for investors. The company's Life Sciences business will be a key growth driver.

PETS : 38.67 (-1.98%)
BDX : 220.31 (-0.55%)
LMNX : 21.51 (-1.06%)
ISRG : 392.48 (-0.34%)
Becton (BDX) Tops Q4 Earnings and Revenues Estimates

Becton, Dickinson???s adjusted earnings of $2.40 per share beat the Zacks Consensus Estimate by 2 cents and increased from $2.12 posted in the year-ago quarter.

BDX : 220.31 (-0.55%)
BD Announces Results For 2017 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2018 Guidance

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.166 billion for the fourth fiscal quarter ended September 30, 2017....

BDX : 220.31 (-0.55%)
Key MedTech Trends to Influence Q3 Earnings: BDX, ABC, TFX

Here we take a look at the major factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe this season.

ABC : 78.84 (-1.83%)
TFX : 266.21 (+1.05%)
BDX : 220.31 (-0.55%)
MDT : 79.49 (+0.29%)
ECL : 131.45 (-0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Becton, Dickinson and Co. is engaged principally in the manufacture and sale of a broad line of supplies, devices and systems used by health care professionals, medical research institutions and the general public. BD's operations consist of three worldwide business segments: Medical Systems, Biosciences,...

See More

Key Turning Points

2nd Resistance Point 222.05
1st Resistance Point 221.18
Last Price 220.31
1st Support Level 219.68
2nd Support Level 219.05

See More

52-Week High 225.23
Last Price 220.31
Fibonacci 61.8% 200.80
Fibonacci 50% 193.26
Fibonacci 38.2% 185.72
52-Week Low 161.29

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart